Cargando…

Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13

Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Falvella, Ana Caroline Brambilla, Smith, Bradley Joseph, Silva-Costa, Licia C., Valença, Aline G. F., Crunfli, Fernanda, Zuardi, Antonio W., Hallak, Jaime E., Crippa, José A., de Almeida, Valéria, Martins-de-Souza, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193732/
https://www.ncbi.nlm.nih.gov/pubmed/34122009
http://dx.doi.org/10.3389/fnmol.2021.673144
_version_ 1783706287046918144
author Falvella, Ana Caroline Brambilla
Smith, Bradley Joseph
Silva-Costa, Licia C.
Valença, Aline G. F.
Crunfli, Fernanda
Zuardi, Antonio W.
Hallak, Jaime E.
Crippa, José A.
de Almeida, Valéria
Martins-de-Souza, Daniel
author_facet Falvella, Ana Caroline Brambilla
Smith, Bradley Joseph
Silva-Costa, Licia C.
Valença, Aline G. F.
Crunfli, Fernanda
Zuardi, Antonio W.
Hallak, Jaime E.
Crippa, José A.
de Almeida, Valéria
Martins-de-Souza, Daniel
author_sort Falvella, Ana Caroline Brambilla
collection PubMed
description Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia symptoms. While oligodendrocytes are known to be relevant targets of antipsychotics, the biochemical knowledge in this regard is still limited. Here we evaluated the molecular pathways modulated by cannabidiol compared to the antipsychotics clozapine (atypical) and haloperidol (typical), additionally evaluating the effects of benztropine, a muscarinic receptor antagonist that displays a protective effect in oligodendrocytes and myelination. For this purpose, we employed nano-chromatography coupled with mass spectrometry to investigate the proteomic response to these drugs both in healthy oligodendrocytic cells and in a cuprizone-based toxicity model, using the human oligodendrocyte precursor cell line MO3.13. Cannabidiol shares similarities of biochemical pathways with clozapine and benztropine, in agreement with other studies that indicated an atypical antipsychotic profile. All drugs tested affected metabolic and gene expression pathways and cannabidiol, benztropine, and clozapine modulated cell proliferation and apoptosis when administered after cuprizone-induced toxicity. These general pathways are associated with cuprizone-induced cytotoxicity in MO3.13 cells, indicating a possible proteomic approach when acting against the toxic effects of cuprizone. In conclusion, although modeling oligodendrocytic cytotoxicity with cuprizone does not represent the entirety of the pathophysiology of oligodendrocyte impairments, these results provide insight into the mechanisms associated with the effects of cannabidiol and antipsychotics against cuprizone toxicity, offering new directions of study for myelin-related processes and deficits.
format Online
Article
Text
id pubmed-8193732
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81937322021-06-12 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13 Falvella, Ana Caroline Brambilla Smith, Bradley Joseph Silva-Costa, Licia C. Valença, Aline G. F. Crunfli, Fernanda Zuardi, Antonio W. Hallak, Jaime E. Crippa, José A. de Almeida, Valéria Martins-de-Souza, Daniel Front Mol Neurosci Molecular Neuroscience Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia symptoms. While oligodendrocytes are known to be relevant targets of antipsychotics, the biochemical knowledge in this regard is still limited. Here we evaluated the molecular pathways modulated by cannabidiol compared to the antipsychotics clozapine (atypical) and haloperidol (typical), additionally evaluating the effects of benztropine, a muscarinic receptor antagonist that displays a protective effect in oligodendrocytes and myelination. For this purpose, we employed nano-chromatography coupled with mass spectrometry to investigate the proteomic response to these drugs both in healthy oligodendrocytic cells and in a cuprizone-based toxicity model, using the human oligodendrocyte precursor cell line MO3.13. Cannabidiol shares similarities of biochemical pathways with clozapine and benztropine, in agreement with other studies that indicated an atypical antipsychotic profile. All drugs tested affected metabolic and gene expression pathways and cannabidiol, benztropine, and clozapine modulated cell proliferation and apoptosis when administered after cuprizone-induced toxicity. These general pathways are associated with cuprizone-induced cytotoxicity in MO3.13 cells, indicating a possible proteomic approach when acting against the toxic effects of cuprizone. In conclusion, although modeling oligodendrocytic cytotoxicity with cuprizone does not represent the entirety of the pathophysiology of oligodendrocyte impairments, these results provide insight into the mechanisms associated with the effects of cannabidiol and antipsychotics against cuprizone toxicity, offering new directions of study for myelin-related processes and deficits. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8193732/ /pubmed/34122009 http://dx.doi.org/10.3389/fnmol.2021.673144 Text en Copyright © 2021 Falvella, Smith, Silva-Costa, Valença, Crunfli, Zuardi, Hallak, Crippa, Almeida and Martins-de-Souza. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Neuroscience
Falvella, Ana Caroline Brambilla
Smith, Bradley Joseph
Silva-Costa, Licia C.
Valença, Aline G. F.
Crunfli, Fernanda
Zuardi, Antonio W.
Hallak, Jaime E.
Crippa, José A.
de Almeida, Valéria
Martins-de-Souza, Daniel
Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
title Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
title_full Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
title_fullStr Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
title_full_unstemmed Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
title_short Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13
title_sort cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line mo3.13
topic Molecular Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193732/
https://www.ncbi.nlm.nih.gov/pubmed/34122009
http://dx.doi.org/10.3389/fnmol.2021.673144
work_keys_str_mv AT falvellaanacarolinebrambilla cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT smithbradleyjoseph cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT silvacostaliciac cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT valencaalinegf cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT crunflifernanda cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT zuardiantoniow cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT hallakjaimee cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT crippajosea cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT dealmeidavaleria cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313
AT martinsdesouzadaniel cannabidioldisplaysproteomicsimilaritiestoantipsychoticsincuprizoneexposedhumanoligodendrocyticcelllinemo313